.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Spotlight

OncClub: Join the Chat on Trending Trials in Cancer
Final results from the Phase 3 ClarIDHy trial
Lively expert panel discussions featuring peer-to-peer exchanges
Long-term efficacy and safety of TRK fusion-positive lung cancer treatment

SpecialtySee All >

Biosimilars
Breast Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Gynecologic Oncology
Head & Neck Cancers
Hematologic Oncology
Immuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Multiple Myeloma

Advertise
About OncLive
Editorial Board
CureToday.com
TargetedOnc.com
CancerNetwork.com
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information

2 Clarke Drive
Suite 100
Cranbury, NJ 08512

Combination Approaches for Metastatic Renal Cell Carcinoma

EP. 1: Historical Perspectives on the Treatment of mRCC

July 30th 2018

EP. 2: Rationale for Combination Therapy in mRCC

July 30th 2018

EP. 3: Cabozantinib in mRCC

July 30th 2018

EP. 4: Nivolumab and Ipilimumab in mRCC

July 30th 2018

EP. 5: Bevacizumab and Interferon in mRCC

July 30th 2018

EP. 6: Antiangiogenic Resistance in mRCC

July 30th 2018

EP. 7: Making Decisions for Second-Line Therapy in mRCC

July 30th 2018

EP. 8: Second-Line Combination Therapy in mRCC

July 30th 2018

EP. 9: Lenvatinib and Everolimus in Relapsed/Refractory mRCC

July 30th 2018

EP. 10: Managing Patients on Lenvatinib/Everolimus in mRCC

July 30th 2018